# Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

> **NCT00095966** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage II Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00095966
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2005-09
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095966, "Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00095966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*